European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics

Descripción del proyecto

Red europea de formación en investigación traslacional del glioblastoma

El glioblastoma (GBM) es un cáncer cerebral muy agresivo y letal, en el que el 85 % de los pacientes fallece en un plazo de dos años. En la actualidad, no existe una terapia eficaz para el GBM y se necesitan urgentemente nuevas opciones de tratamiento. El proyecto GLIOTRAIN, financiado por la iniciativa Marie Skłodowska-Curie Actions, se centrará en el desarrollo de una red europea de formación en investigación de catorce organizaciones procedentes de ocho países para formar a quince jóvenes y creativos investigadores. El objetivo de GLIOTRAIN es descubrir nuevas estrategias terapéuticas para el tratamiento del GBM, utilizando la secuenciación de nueva generación, la medicina de sistemas y la multiómica integradora para comprender los mecanismos de resistencia de la enfermedad. La red del proyecto preparará a una nueva generación de científicos para abordar la investigación traslacional y la atención clínica del GBM.

Objetivo

Glioblastoma (GBM) is the most frequent, aggressive and lethal of all brain tumours. It has a universally fatal prognosis with 85% of patients dying within two years. New treatment options and effective precision medicine therapies are urgently required. This can only be achieved by focused multi-sectoral industry-academia collaborations in newly emerging, innovative research disciplines. GLIOTRAIN will exploit the intractability of GBM to address European applied biomedical research training needs. The ETN, which comprises 9 beneficiaries and 14 partner organisations from 8 countries, will train 15 innovative, creative and entrepreneurial ESRs. The research objective of GLIOTRAIN is to identify novel therapeutic strategies for application in GBM, while implementing state of the art next generation sequencing, systems medicine and integrative multi-omics to unravel disease resistance mechanisms. Research activities incorporate applied systems medicine, integrative multi-omics leveraging state of the art platform technologies, and translational cancer biology implementing the latest clinically relevant models. The consortium brings together leading European and international academics, clinicians, private sector and not-for-profit partners across GBM fields of tumour biology, multi-omics, drug development, clinical research, bioinformatics, computational modelling and systems biology. Thus, GLIOTRAIN will address currently unmet translational research and clinical needs in the GBM field by interrogating innovative therapeutic strategies and improving the mechanistic understanding of disease resistance. The GLIOTRAIN ETN addresses current needs in academia and the private sector for researchers that have been trained in an environment that spans translational research, medicine and computational biology, and that can navigate confidently between clinical, academic and private sector environments to progress applied research findings towards improved patient outcomes.

Coordinador

ROYAL COLLEGE OF SURGEONS IN IRELAND
Aportación neta de la UEn
€ 1 062 698,40
Dirección
ST STEPHEN'S GREEN 123
2 Dublin
Irlanda

Ver en el mapa

Región
Ireland Northern and Western Border
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 1 062 698,40

Participantes (8)

Socios (14)